Company Information

    Escalier Biosciences was founded on January 2016. The company is based in Encinitas, CA, USA . The number of employees in Escalier Biosciences is less than 50. Escalier biosciences bv is a privately held biopharmaceutical company.
      If you are the founder or part of the founding team, please tell the world your story


          Funding & investors

          Escalier Biosciences has received 1 rounds of venture funding. The total funding amount is around $19M.

            Similar Companies [beta]

              Venture Categories

                Active Venture Investors




                  Venture Competitors

                    News

                        Escalier Biosciences - Blog

                          • Escalier Doses First Patient with ESR-114 and Announces Clinical Advisory Board

                          • Commences study to assess novel RORγt inhibitor for the treatment of psoriasisRecruits key opinion leaders to guide clinical development of its RORγt programsNIJMEGEN, The Netherlands and Encinitas, California, August 13, 2018 – Escalier Biosciences, BV, a privately held biopharmaceutical company and a leader in the field of immunology, today announced that the first patient has been dosed in a Phase 1/2a study evaluating ESR-114 topical gel in patients with mild-to-moderate psoriasis.The post Escalier Doses First Patient with ESR-114 and Announces Clinical Advisory Board appeared first on Escalier Biosciences.
                          • Sander van Deventer, M.D., Ph.D.

                          • Dr. van Deventer is currently an Operating Partner at Forbion Capital Partners. In addition, Sander is a professor in Translational Gastroenterology at the University of Leiden. In 1995, he became director of the laboratory for Experimental Internal Medicine at the Academic Medical Centre in Amsterdam. From 2001 until 2004, he chaired the Department of Gastroenterology […]The post Sander van Deventer, M.D., Ph.D. appeared first on Escalier Biosciences.
                          • Escalier Biosciences Raises $19 Million to Develop its Topical and Systemic RORγt Therapies for Psoriasis and other Autoimmune Diseases

                          • Advancing Escalier’s drug candidates through human proof-of-concept studiesNIJMEGEN, The Netherlands and ENCINITAS, California, – Escalier Biosciences BV, a privately held biopharmaceutical company, today announced the closing of a $19 million Series B financing. The round was led by Forbion with existing investors New Science Ventures and BioGeneration Ventures (BGV) completing the round. Escalier is developing both topical and oral RORγt drug candidates for psoriasis and expects to be in the clinic with its topical compound in mid 2018.The post Escalier Biosciences Raises $19 Million to Develop its Topical and Systemic ROR<span class='greek'>γ</span>t Therapies for Psoriasis and other Autoimmune Diseases appeared first on Escalier Biosciences.
                          • Norman C. Selby

                          • Norman serves on the board of directors of Infinity Pharmaceuticals, Inc., Merz GmbH & Co. KGaA, Metamark Genetics, Inc., National Parks Conservation Association, Ralph Lauren Center, Ulthera, Inc., Memorial Sloan-Kettering Cancer Center and Central Park Conservancy, Inc. Norman was previously a Senior Advisor with Perseus LLC, Chairman of Windhover Information, Inc., President & Chief Executive […]The post Norman C. Selby appeared first on Escalier Biosciences.
                          • Willam Sandborn, M.D.

                          • Dr. Sandborn serves as the Chief of Division of Gastroenterology at University of California San Diego Inflammatory Bowel Disease Center and Professor of Clinical Medicine. He served as Chief of the Division of Gastroenterology for the UC San Diego Health System. Dr. Sandborn has served as head of the Division of Gastroenterology and Hepatology, Mayo Clinic, […]The post Willam Sandborn, M.D. appeared first on Escalier Biosciences.
                          • Alexa Kimball, M.D., M.P.H.

                          • Alexa B. Kimball, MD, MPH is a Professor of Dermatology at Harvard Medical School and CEO and President of Harvard Medical Faculty Physicians at Beth Israel Deaconess Medical Center, a large academic multi-specialty 501(c)3 corporation based in Boston, Massachusetts. Dr. Kimball also co-chairs the Beth Israel Lahey Health Performance Network Board and is on the […]The post Alexa Kimball, M.D., M.P.H. appeared first on Escalier Biosciences.

                          Share:     facebook    twitter    linkedin    reddit    email

                            Ventures Media is one of the largest startup and venture capital communities for startup and venture capital funding information and analysis.

                            Leave a Reply

                            Your email address will not be published. Required fields are marked *